Management strategies for patients with cytomegalovirus retinitis

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue SUPPL. 1, 1997, Pages

  Hardy, W David ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pacific Oaks Medical Group   (United States)

Author keywords

AIDS; Cidofovir; CMV; Foscarnet; Ganciclovir; Ganciclovir implant; HIV; HPMPC; Oral ganciclovir; Probenecid; Resistance; Treatment team

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CIDOFOVIR; CORTICOSTEROID; COTRIMOXAZOLE; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; PREDNISONE; PROBENECID; THEOPHYLLINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANIMAL MODEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL DECISION MAKING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RETINITIS; TREATMENT PLANNING;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0030891911     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199700001-00003     Document Type: Conference Paper

References (19)

1. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, and the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
2. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115:575-82.
3. Jacobson MA. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res Hum Retroviruses 1994;10:917-23.
4. Hoover DR, Saah AJ, Bacellar H, et al., for the Multicenter AIDS Cohort Study. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993;329: 1922-6.
5. Hoover DR. The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease: a review of the literature. Drugs 1995;49:20-36.
6. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
7. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
8. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65-74.
9. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996;114:23-33.
10. Drew WL, Ives D, Lalezari JP, et al., for the Syntex Cooperative Oral Ganciclovir Study Group. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
11. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
12. Lalezari JP, Stagg RJ, Kuppermann BD, et al. A randomized, controlled trial of intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997 (in press).
13. Lalezari J, Kemper C, Stagg R, et al. A randomized, controlled study of the safety and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS [Abstract]. Abstracts of the XI International Conference on AIDS 1996; 226:Th.B.304.
14. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Review - antiviral portrait series: cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother 1996; 7:115-27.
15. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl] cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analog. J Infect Dis 1995;171:788-96.
16. Gaines K, Wong R, Jung D, Cimoch P, Lavelle J, Pollard R. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid [Abstract]. Abstracts of Xth International Conference on AIDS 1994;7:004B.
17. Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis 1994;13(suppl 2): 34-40.
18. Hardy D. Current management of cytomegalovirus infection: treatment and prophylaxis. Am J Health Suppl Pharm 1996;53:S12-6.
19. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665-73.